Deep Dive Into Ocular Therapeutix Stock: Analyst Perspectives (6 Ratings)
Portfolio Pulse from Benzinga Insights
Ocular Therapeutix (NASDAQ:OCUL) has received mixed ratings from 6 analysts over the past three months, with a majority being bullish. The average 12-month price target is $16.17, slightly down from the previous $16.25. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.
June 14, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target is $16.17, slightly down from $16.25. Analysts have adjusted their ratings and price targets in response to market conditions and company performance.
The majority of analysts are bullish on OCUL, which is a positive indicator for the stock. However, the slight decrease in the average price target suggests some caution. The overall impact is likely positive in the short term due to the bullish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100